Showing 271-280 of 20328 results for "".
Behind the Screens: Innovations in Type 1 Diabetes Clinical Trials—From Immunomodulation to Screening Strategies and Advanced Cell Therapies
https://reachmd.com/programs/cme/behind-the-screens-innovations-in-type-1-diabetes-clinical-trialsfrom-immunomodulation-to-screening-strategies-and-advanced-cell-therapies/39701/Behind the Screens: Innovations in Type 1 Diabetes Clinical Trials—From Immunomodulation to Screening Strategies and Advanced Cell TherapiesUpdated Target Blood Sugar Levels for Type 2 Diabetes Patients
https://reachmd.com/programs/what-your-patients-are-talking-about/updated-target-blood-sugar-levels-type-2-diabetes-patients/7387/According to a report in the New England Journal of Medicine, doctors now have updated targets for lowering blood sugar in their Type 2 diabetes patients.Prova Education -- Improving Treatment for Type 2 Diabetes: Overcoming Barriers to Optimal Care, Part 3
https://reachmd.com/programs/grand-rounds-nation/prova-education-improving-treatment-for-type-2-diabetes-overcoming-barriers-to-optimal-care-part-3/6566/This program will address the increasing prevalence of overweight, obese and type 2 diabetes conditions in our patient population. Physicians and healthcare professionals are confronted with multiple treatment and management challenges for type 2 diabetes. Treatment goals and care-delivery systems oProva Education -- Improving Treatment for Type 2 Diabetes: Overcoming Barriers to Optimal Care, Part 2
https://reachmd.com/programs/grand-rounds-nation/prova-education-improving-treatment-for-type-2-diabetes-overcoming-barriers-to-optimal-care-part-2/6565/This program will address the increasing prevalence of overweight, obese and type 2 diabetes conditions in our patient population. Physicians and healthcare professionals are confronted with multiple treatment and management challenges for type 2 diabetes. Treatment goals and care-delivery systems oProva Education -- Improving Treatment for Type 2 Diabetes: Overcoming Barriers to Optimal Care, Part 1
https://reachmd.com/programs/grand-rounds-nation/prova-education-improving-treatment-for-type-2-diabetes-overcoming-barriers-to-optimal-care-part-1/6564/This program will address the increasing prevalence of overweight, obese and type 2 diabetes conditions in our patient population. Physicians and healthcare professionals are confronted with multiple treatment and management challenges for type 2 diabetes. Treatment goals and care-delivery systems oUpdates in the Classification & Diagnosis of Type 2 Diabetes
https://reachmd.com/programs/diabetes-discourse/updates-in-the-classification-diagnosis-of-type-2-diabetes/6641/Host Dr. Farhad Zangeneh welcomes Dr. Kathleen "Kittie" Wyne from the The Methodist Hospital Research Institute (TMHRI) in Houston where she also coordinates their clinical research program in The Diabetes Research Center. Dr. Wyne discusses the changing classification of diabetes and pre-diabetes aNovel Treatments for Diabetes
https://reachmd.com/programs/medical-breakthroughs-from-penn-medicine/novel-treatments-for-diabetes/1787/Dr. Lazar discusses exciting new innovations in our approach to both type I and type II diabetes including Islet cell transplantation, medications for beta cell preservation and new insights into the control of obesity.Diabetic Retinopathy I
https://reachmd.com/programs/revealing-retina/diabetic-retinopathy-i/1727/Tune in to hear the first in a monthly series entitled, "The Revealing Retina". Dr. Roy Levit, host and president of the American Retina Fundation, welcomes Dr. Suber Huang, Director of Vitreoretinal Diseases and Surgery at University Hospitals of Cleveland, and Medical Director and Treasurer for UnThe Case for Pancreas-After-Kidney Transplantation in Type 1 Diabetics
https://reachmd.com/programs/advances-in-transplantation/the-case-for-pancreas-after-kidney-transplantation-in-type-1-diabetics/6379/Although most patients with type 1 diabetes are able to rely on insulin to effectively manage their condition, sometimes insulin is not enough. When should these patients consider pancreas and/or kidney transplant? Dr. Jonathan Fridell, surgical director of the pancreas transplant program at IndianaRisk of RVO in Type 2 Diabetes: GLP-1 Receptor Agonists Versus DPP-4 Inhibitors
https://reachmd.com/programs/eye-on-ocular-health/risk-of-rvo-in-type-2-diabetes-glp-1-receptor-agonists-versus-dpp-4-inhibitors/37663/Among patients with type 2 diabetes, retinal vein occlusion (RVO) is a significant clinical challenge, as well as a leading cause of irreversible vision loss. With vascular health at the center of diabetes management, the choice of glucose-lowering therapy may influence ocular outcomes. Join Dr. Mim